NCT06515262View on ClinicalTrials.gov

Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
BIOLOGICAL

Anti-BCMA-GPRC5D CAR-T cells infusion

Subiects who meet the enrollment conditions will receive intravenous infusion of anti-BCMA-GPRC5D CAR-T Cells after lymphodepleting therapy.

Trial Locations (1)

650100

RECRUITING

Sanbin Wang, Kunming

All Listed Sponsors
collaborator

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY

lead

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

OTHER